A recent meta-analysis of two RCTs questioned the potential risk of HF hospitalization following the introduction of GLP1-RA (liraglutide and exenatide) in T2DM patients with overt HF in the setting of HFrEF, finding a 50% augmented risk (OR 1.49, 95% CI 1.05–2.10, p = 0.02; I2 = 0%) [46]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.